Penn Vet | Cancer Clinical Trial - Evaluation of Nemo Binding Domain (NBD) peptide for dogs with soft tissue sarcoma
Contact
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
610-444-5800
Directions
Ryan Hospital Philadelphia, PA
Emergencies:
215-746-8911
Appointments:
215-746-8387
Directions

Evaluation of Nemo Binding Domain (NBD) peptide for dogs with soft tissue sarcoma

Nov 12, 2019

Purpose:

  • To investigating whether NBD peptide can promote tumor cell death in canine soft tissue sarcomas (STS) that have active NF-KB (signaling pathway) activity

Eligibility criteria:

  • Confirmed/highly suspected diagnosis of STS obtained either via FNA or biopsy
  • Dog is otherwise healthy
  • No evidence of pulmonary metastasis

Basic study design:

  • Screening visit - staging (blood work, urinalysis, chest x-rays) + incisional biopsy of the mass (to confirm diagnosis of sarcoma and also to determine whether the NF-KB pathway is overactive in the mass)
  • If the overactive pathway is identified, then within one week:
    • Daily tumor injections for 4 days with the NBD peptide (outpatient procedure)
    • On day 5, the tumor is removed via definitive surgical excision (or if it is nonresectable, a second incisional biopsy will be obtained).
  • Following surgery - recheck visits every 2 months for a total of 3 visits (physical exam and chest x-rays).

Covered costs:

  • Physical examinations throughout the course of the study.
  • General health blood and urine tests at screening and one day after the last NBD peptide administration.
  • Chest x-rays at screening and every 2 months there-after for a total of 6 months.
  • Two biopsies of the tumor performed under light sedation or general anesthetic.
  • Immunohistochemical analysis of the tumor (to determine NF-kappaB expression).
  • $300 towards definitive surgery (to be performed one day following the last NBD peptide administration. This would replace the second biopsy procedure)
  • Treatment of any toxicity your dog develops secondary to NBD peptide administration.

 

Please contact the VCIC at 215-573-0302 or vcic@vet.upenn.edu for more information about this study.